NCT05594992View on ClinicalTrials.gov

An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 22, 2023

Primary Completion Date

February 28, 2028

Study Completion Date

February 28, 2028

Conditions
Mucopolysaccharidosis II
Interventions
DRUG

JR-141

IV infusion, 2.0 mg/kg/week

Trial Locations (9)

19104

Children's Hospital of Philadelphia, Philadelphia

94609

UCSF Benioff Children's Hospital Oakland, Oakland

Unknown

Hospital Universitario Austral, Buenos Aires

Hospital de Clínicas de Porto Alegre, Porto Alegre

Instituto de Genética e Erros Inatos do Metabolismo, São Paulo

Hôpital Femme Mère Enfant, Bron

Universitätsklinikum Hamburg-Eppendorf, Hamburg

Osp. Pediatrico Bambino Gesù, IRCCS, Rome

Hospital Sant Joan de Déu, Barcelona

Sponsors
All Listed Sponsors
lead

JCR Pharmaceuticals Co., Ltd.

INDUSTRY

NCT05594992 - An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects | Biotech Hunter | Biotech Hunter